Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report)'s stock price reached a new 52-week high during trading on Wednesday . The company traded as high as $17.53 and last traded at $17.39, with a volume of 1159408 shares changing hands. The stock had previously closed at $17.44.
Analysts Set New Price Targets
A number of brokerages recently weighed in on CLYM. BTIG Research boosted their price objective on shares of Climb Bio from $19.00 to $20.00 and gave the stock a "buy" rating in a report on Thursday, June 11th. Wedbush increased their target price on Climb Bio from $17.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, July 27th. Weiss Ratings reissued a "sell (d-)" rating on shares of Climb Bio in a report on Friday, July 17th. Robert W. Baird set a $21.00 price target on Climb Bio in a research note on Wednesday, May 6th. Finally, Truist Financial upped their price target on Climb Bio from $17.00 to $25.00 and gave the company a "buy" rating in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $22.75.
Get Our Latest Stock Analysis on CLYM
Climb Bio Stock Down 0.3%
The stock has a market capitalization of $998.88 million, a PE ratio of -20.95 and a beta of 0.08. The firm's fifty day moving average price is $12.98 and its two-hundred day moving average price is $9.85.
Climb Bio (NASDAQ:CLYM - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.03. As a group, analysts predict that Climb Bio, Inc. will post -0.84 EPS for the current year.
Institutional Trading of Climb Bio
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC bought a new stake in shares of Climb Bio during the 1st quarter valued at $27,000. Goldman Sachs Group Inc. bought a new position in Climb Bio in the 1st quarter worth approximately $147,000. Marshall Wace LLP purchased a new stake in Climb Bio during the second quarter valued at approximately $46,000. Qube Research & Technologies Ltd purchased a new stake in Climb Bio during the second quarter valued at approximately $43,000. Finally, Jane Street Group LLC bought a new stake in shares of Climb Bio in the 2nd quarter valued at approximately $184,000. 69.76% of the stock is owned by hedge funds and other institutional investors.
Climb Bio Company Profile
(
Get Free Report)
Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company's mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.
At the heart of Climb Bio's approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
